Mild Cognitive Impairment in Breast Cancer Patients (HippoPCI)
Hippocampal Predictors of Cognitive Impairment (HippoPCI) in Breast Cancer Patients
研究概览
详细说明
This study aims to identify neuroimaging biomarkers for predicting mild cognitive impairment (MCI) in breast cancer patients receiving adjuvant chemo and/or hormonal therapy by examining hippocampal-cortical neurocircuitry. Adjuvant therapies increase long-term survival, but produce changes in cognitive function in 30% (up to 70%) of women on average with breast cancer. Cognitive decline negatively impacts quality of life in patients and their supporters. Therefore, early identification of patients at risk for developing treatment-related cognitive impairment is needed to develop potential prevention or treatment options and prevent further decline. Our recent work demonstrates that patients receiving adjuvant hormonal treatment exhibit decline in cognition as soon as three months post treatment. Although neuroimaging studies have identified brain changes associated with chemotherapy ("chemo brain", no investigation has assessed the type and severity of such changes following hormonal therapy, nor has any study determined which individuals are at greatest risk for cognitive impairment.
Our central hypothesis is that measures of the hippocampal-cortical integrity can be used to predict cognitive decline, and changes of specific domains of cognitive performance in patients receiving adjuvant therapy over time will be related to changes in specific components of this circuitry over time.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Northwestern University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Participants will be recruited from the following sites, all affiliated with Northwestern University Feinberg School of Medicine (NUFSM): a) outpatient facility at Galter Pavilion of Northwestern Medicine; b) Maggie Daley Center for Women's Cancer Care at Prentice Women's Hospital; and c) Lynn Sage Comprehensive Breast Cancer Center at Prentice Women's Hospital.
Participants will also be recruited a) via advertisement in local newspapers, craigslist, Robert H. Lurie Comprehensive Cancer Center (RHLCC) Cancer Survivorship Institute website, and at community programs that serve cancer patients, including hospitals and support groups; and b) from community educational events sponsored by RHLCC, Women's Health Research Institute, and Cognitive Neurology and Alzheimer's Disease Center (CNADC).
描述
Inclusion Criteria:
- Female, within the age range of 40-70
- HT Patients - any stage of breast cancer without brain metastasis, will undergo hormonal therapy without chemotherapy
- CT and HT Patients - any stage of breast cancer without brain metastasis, will undergo chemotherapy and hormonal therapy
- CT Patients - any stage of breast cancer without brain metastasis, has undergone surgery prior to screening, will undergo chemotherapy without hormonal therapy
- RT or NT Patients - any stage of breast cancer without brain metastasis, will not undergo chemotherapy or hormonal therapy; may undergo radiation therapy or have no therapy
- Controls - cognitively normal on the basis of annual neuropsychological and research neurological examinations done as part of the Uniform Data Set (UDS), of the NIA Alzheimer's Disease Centers (ADC) program, recruited from the NU CNADC Clinical Core.
- All subjects must have given signed, informed consent prior to registration on study.
Exclusion Criteria:
- Individuals who report significant medical, neurologic, or psychiatric illness, including but not limited to:
- Major depression
- Schizophrenia
- ADHD
- Autism
- Alzheimer's disease
- Dementia
- Obsessive-compulsive disorder
- Post-traumatic stress disorder
- Individuals with an Inventory of Depressive Symptomatology - Self Report (IDS-SR) score of 30 or higher, since this level of depression could affect cognitive test performance.
Brain surgery or head injury
- Individuals reporting previous head injury
- Individuals requiring neurosurgical procedures
Ineligibility for MRI scanning, including but not limited to:
- Individuals who have non-MRI compatible medical implants or devices
- Individuals who have any potential metal in their bodies
- Individuals who have claustrophobia
- Individuals with permanent makeup
- Individuals reporting consumption of drugs that would affect cognition (neuropsychiatric or illicit)
- Individuals indicating a history of breast cancer will be excluded from the healthy control group
- Women who are pregnant or are planning to become pregnant during study.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
HT Patients
any stage of breast cancer without brain metastasis, will undergo hormonal therapy without chemotherapy
|
|
CT and HT Patients
any stage of breast cancer without brain metastasis, will undergo chemotherapy and hormonal therapy
|
|
CT Patients
any stage of breast cancer without brain metastasis, has undergone surgery prior to screening, will undergo chemotherapy without hormonal therapy
|
|
RT or NT Patients
any stage of breast cancer without brain metastasis, will not undergo chemotherapy or hormonal therapy; may undergo radiation therapy or have no therapy
|
|
Controls
healthy, cognitively normal subjects
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rates of change in cognitive function from before treatment to after treatment initiation
大体时间:approximately 6 months
|
Measured using a neuropsychological test battery
|
approximately 6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rates of change of brain structure from before treatment to after treatment initiation
大体时间:approximately 6 months
|
Measured using structural MRI scan
|
approximately 6 months
|
|
Rates of change of brain function from before treatment to after treatment initiation
大体时间:approximately 6 months
|
Measured using a functional MRI scan
|
approximately 6 months
|
合作者和调查者
调查人员
- 首席研究员:Lei Wang, PhD、Northwestern University
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.